Simple new prenatal blood test for early and accurate detection of major chromosomal abnormalities

Simple new prenatal blood test for early and accurate detection of major chromosomal abnormalities

Molecular Diagnostics

October 22, 2015

Multiplicom is proud to launch Clarigo™, a new CE-IVD1 non-invasive prenatal test (NIPT). This highly accurate blood test will enable genetic analysis laboratories to detect the presence or absence of major chromosomal abnormalities such as trisomy 21 (Down’s syndrome), 18 (Edwards’ syndrome) and 13 (Patau syndrome), in the fetus, as early as in the first trimester of pregnancy by analysis of the fetus’s DNA in the maternal blood.

Clarigo enables an optimal workflow for low to high throughput sample processing that further reduces the overall cost to a level that will make NIPT affordable for all pregnant women as an integral part of prenatal care.

The targeted design of Clarigo enables highly accurate trisomy calling of chromosomes 21, 18 and 13 based on only 2M reads per sample, which is several times less than for generally used shotgun approaches. Data analysis and interpretation is automated with the dedicated Clarigo™ Reporter software developed at Multiplicom and empowered by proprietary algorithms. The Clarigo Reporter further includes an intrinsic quality control assessment and provides information on the fetal fraction for each sample and optionally on fetal gender.

Explore plasmid preparation possibilities in this handy eGuide

Explore plasmid preparation possibilities in this handy eGuide

Molecular Diagnostics

Performing plasmid purification? Then you must be familiar with QIAGEN's plasmid prep kits! But are you using the optimal kit for your applications? Now you can get an overview of our kits, all in one eGuide. Check out the DNA yields, processing times and culture volumes at a glance and find the optimal protocol today.

January 12, 2017 More +
New CFTR MASTR Dx validated for dried blood spots

New CFTR MASTR Dx validated for dried blood spots

Molecular Diagnostics

Multiplicom is pleased to announce that CFTR MASTR™ Dx has been successfully validated for an additional sample type: dried blood spots. The CE-IVD claim is now extended to include DNA extracted from dried blood spots, allowing you to use the assay for routine neonatal screening.

March 12, 2015 More +
Ready to make an enquiry Call us on: + 961 1 39 66 77
Or email us